Obesity Therapy
Selective 5-HT2C agonists show promise in obesity treatments
Published in Obesity and Diabetes Week, May 1st, 2006
"Activation of central 5-HT2C receptors as a strategy for appetite suppression and weight control is supported by animal pharmacology and human clinical studies. Considerable evidence comes from the weight-loss effects of fenfluramine, a nonselective 5-HT2C agonist," scientists in the United States report in their review.
"Advances in molecular pharmacology have led to an understanding of the effects of 5-HT2C receptor activation on food intake and satiety, in addition to providing insight into the causes of cardiac valvular insufficiency and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity & Sleep Deprivation
Leptin deficiency disrupts the regulation of sleep architecture and diurnal rhythmicity - Obesity Epidemiology
ADRB2 gene accounts for obesity-related phenotypes in males - Obesity Pathogenesis
Adapter p62 is linked to mature-onset obesity and insulin resistance in mouse model - Obesity Therapy
Initial trocar placement is safe and effective in morbidly obese patients - Angiogenesis
Data from angiogenesis program using cell labeling technology reported at conference - Angiology
New findings from Canada, the United States and the United Kingdom in the area of angiology described - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
